Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 121

1.

Etiologic diagnosis of jaw osteonecrosis, other than bisphosphonate and radiotherapy related osteonecrosis.

Magremanne M, Picheca S, Reychler H.

Rev Stomatol Chir Maxillofac Chir Orale. 2014 Feb;115(1):45-50. doi: 10.1016/j.revsto.2013.12.012. Epub 2014 Jan 21. Review.

PMID:
24456913
2.

[Etiologic diagnosis of jaw osteonecrosis, other than bisphosphonate and radiotherapy related osteitis].

Magremanne M, Picheca S, Reychler H.

Rev Stomatol Chir Maxillofac Chir Orale. 2014 Feb;115(1):e1-7. doi: 10.1016/j.revsto.2013.12.010. Epub 2014 Jan 21. Review. French.

PMID:
24456912
3.

Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review.

Almazrooa SA, Woo SB.

J Am Dent Assoc. 2009 Jul;140(7):864-75. Review.

PMID:
19571050
4.

Epidemiology and pathogenesis of osteonecrosis of the jaw.

Reid IR, Cornish J.

Nat Rev Rheumatol. 2011 Nov 29;8(2):90-6. doi: 10.1038/nrrheum.2011.181. Review.

PMID:
22124271
5.

[Diabetes mellitus and bisphosphonate-related osteonecrosis of the jaws].

Urade M.

Clin Calcium. 2009 Sep;19(9):1332-8. doi: CliCa090913321338. Review. Japanese.

PMID:
19721206
6.

Oral cancer: comprehending the condition, causes, controversies, control and consequences. 17. Osteonecrosis.

Madrid C, Scully C.

Dent Update. 2012 Jun;39(5):377-9. No abstract available.

PMID:
22852516
7.

Diagnosis and Staging of Medication-Related Osteonecrosis of the Jaw.

Ruggiero SL.

Oral Maxillofac Surg Clin North Am. 2015 Nov;27(4):479-87. doi: 10.1016/j.coms.2015.06.008. Epub 2015 Aug 18. Review.

PMID:
26293329
8.

Osteonecrosis of jaw beyond antiresorptive (bone-targeted) agents: new horizons in oncology.

Fusco V, Santini D, Armento G, Tonini G, Campisi G.

Expert Opin Drug Saf. 2016 Jul;15(7):925-35. doi: 10.1080/14740338.2016.1177021. Epub 2016 May 3. Review.

PMID:
27074901
9.

Bisphosphonate-induced necrosis of the jaws: a reconstructive nightmare.

Gevorgyan A, Enepekides DJ.

Curr Opin Otolaryngol Head Neck Surg. 2008 Aug;16(4):325-30. doi: 10.1097/MOO.0b013e328304b445. Review.

PMID:
18626250
10.

Antiresorptive drug-related osteonecrosis of the jaw.

Uyanne J, Calhoun CC, Le AD.

Dent Clin North Am. 2014 Apr;58(2):369-84. doi: 10.1016/j.cden.2013.12.006. Review.

PMID:
24655528
11.

New cancer therapies and jaw necrosis.

Patel V, Kelleher M, Sproat C, Kwok J, McGurk M.

Br Dent J. 2015 Sep 11;219(5):203-7. doi: 10.1038/sj.bdj.2015.680. Review.

PMID:
26361116
12.

Prevalence of bisphosphonate associated osteonecrosis of the jaw within the field of osteonecrosis.

Walter C, Grötz KA, Kunkel M, Al-Nawas B.

Support Care Cancer. 2007 Feb;15(2):197-202. Epub 2006 Aug 29.

PMID:
16941133
13.

Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.

Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Al Mardini M, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, St-Marie LG, Brown J, Evans AW, Rios L, Compston JE; Canadian Association of Oral and Maxillofacial Surgeons..

J Rheumatol. 2008 Jul;35(7):1391-7. Epub 2008 Jun 1. Erratum in: J Rheumatol. 2008 Oct;35(10):2084. J Rheumatol. 2008 Aug;35(8):1688.

PMID:
18528958
14.

United Kingdom nationwide study of avascular necrosis of the jaws including bisphosphonate-related necrosis.

Rogers SN, Palmer NO, Lowe D, Randall C.

Br J Oral Maxillofac Surg. 2015 Feb;53(2):176-82. doi: 10.1016/j.bjoms.2014.11.008. Epub 2014 Dec 11.

PMID:
25497376
15.

Epidemiologic studies are needed to clarify whether dental modalities could be predictors of bisphosphonate osteonecrosis of the jaw in breast cancer patients.

Kyrgidis A, Andreadis C.

Oncologist. 2009 Jan;14(1):101-2; author reply 103. doi: 10.1634/theoncologist.2008-0155. No abstract available.

16.

Jaw osteonecrosis related to bisphosphonate therapy: a severe secondary disorder.

Dannemann C, Grätz KW, Riener MO, Zwahlen RA.

Bone. 2007 Apr;40(4):828-34. Epub 2007 Jan 22.

PMID:
17236837
17.

Bisphosphonate-related osteonecrosis of the jaw: the role of actinomyces.

Naik NH, Russo TA.

Clin Infect Dis. 2009 Dec 1;49(11):1729-32. doi: 10.1086/648075.

PMID:
19886792
19.

Tetracycline bone fluorescence: a valuable marker for osteonecrosis characterization and therapy.

Pautke C, Bauer F, Bissinger O, Tischer T, Kreutzer K, Steiner T, Weitz J, Otto S, Wolff KD, Stürzenbaum SR, Kolk A.

J Oral Maxillofac Surg. 2010 Jan;68(1):125-9. doi: 10.1016/j.joms.2009.05.442.

PMID:
20006166
20.

American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update.

Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B; American Association of Oral and Maxillofacial Surgeons..

J Oral Maxillofac Surg. 2009 May;67(5 Suppl):2-12. doi: 10.1016/j.joms.2009.01.009. No abstract available.

PMID:
19371809

Supplemental Content

Support Center